- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Obesity
Volume 2013 (2013), Article ID 457047, 9 pages
High-Fat Diet-Induced Alterations in the Feeding Suppression of Low-Dose Nisoxetine, a Selective Norepinephrine Reuptake Inhibitor
1Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey,
84 Lipman Drive, New Brunswick, NJ 08901, USA
2Graduate Program in Endocrinology and Animal Biosciences, Rutgers, The State University of New Jersey, 84 Lipman Drive, New Brunswick, NJ 08901, USA
Received 19 October 2012; Accepted 17 December 2012
Academic Editor: Alfredo Halpern
Copyright © 2013 Nicholas T. Bello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. N. Ginsberg and P. R. Maccallum, “The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus,” Journal of the CardioMetabolic Syndrome, vol. 4, no. 2, pp. 113–119, 2009.
- E. Szczepanska-Sadowska, A. Cudnoch-Jedrzejewska, M. Ufnal, and T. Zera, “Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases,” Journal of Physiology and Pharmacology, vol. 61, pp. 509–521, 2010.
- J. E. Ahlskog and B. G. Hoebel, “Overeating and obesity from damage to a noradrenergic system in the brain,” Science, vol. 182, no. 4108, pp. 166–169, 1973.
- S. Kasparov and A. G. Teschemacher, “Altered central catecholaminergic transmission and cardiovascular disease,” Experimental Physiology, vol. 93, no. 6, pp. 725–740, 2008.
- L. Rinaman, “Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions,” American Journal of Physiology, vol. 300, no. 2, pp. R222–R235, 2011.
- S. Ritter, N. L. Pelzer, and R. C. Ritter, “Absence of glucoprivic feeding after stress suggests impairment of noradrenergic neuron function,” Brain Research, vol. 149, no. 2, pp. 399–411, 1978.
- R. J. Valentino, A. L. Curtis, M. E. Page, L. A. Pavcovich, and S. M. Florin-Lechner, “Activation of the locus ceruleus brain noradrenergic system during stress: circuitry, consequences, and regulation,” Advances in Pharmacology, vol. 42, pp. 781–784, 1998.
- N. T. Bello and M. R. Zahner, “Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity,” Current Opinion in Investigational Drugs, vol. 10, no. 10, pp. 1105–1116, 2009.
- D. J. Heal, J. Gosden, and S. L. Smith, “What is the prognosis for new centrally-acting anti-obesity drugs?” Neuropharmacology, vol. 63, pp. 132–146, 2012.
- R. B. Rothman and E. J. Hendricks, “Phentermine cardiovascular safety,” American Journal of Emergency Medicine, vol. 27, no. 8, pp. 1010–1013, 2009.
- D. Rucker, R. Padwal, S. K. Li, C. Curioni, and D. C. W. Lau, “Long term pharmacotherapy for obesity and overweight: updated meta-analysis,” British Medical Journal, vol. 335, no. 7631, pp. 1194–1199, 2007.
- L. Lemberger, S. Terman, H. Rowe, and R. Billings, “The effect of nisoxetine (Lilly compound 94939), a potential antidepressant, on biogenic amine uptake in man,” British Journal of Clinical Pharmacology, vol. 3, no. 2, pp. 215–220, 1976.
- D. T. Wong and F. P. Bymaster, “The comparison of fluoxetine and nisoxetine with tricyclic antidepressants in blocking the neurotoxicity of p chloroamphetamine and 6 hydroxydopamine in the rat brain,” Research Communications in Chemical Pathology and Pharmacology, vol. 15, no. 2, pp. 221–231, 1976.
- S. C. Cheetham, J. A. Viggers, S. A. Butler, M. R. Prow, and D. J. Heal, “[3H]nisoxetine—a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments,” Neuropharmacology, vol. 35, no. 1, pp. 63–70, 1996.
- S. Kelwala, M. Stanley, and S. Gershon, “History of antidepressants: successes and failures,” Journal of Clinical Psychiatry, vol. 44, no. 5, pp. 40–48, 1983.
- T. Belej, D. Manji, S. Sioutis, H. M. T. Barros, and J. N. Nobrega, “Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects,” Brain Research, vol. 736, no. 1-2, pp. 287–296, 1996.
- S. R. Tella, “Effects of monoamine reuptake inhibitors on cocaine self-administration in rats,” Pharmacology Biochemistry and Behavior, vol. 51, no. 4, pp. 687–692, 1995.
- S. K. Billes and M. A. Cowley, “Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice,” Neuropsychopharmacology, vol. 32, no. 4, pp. 822–834, 2007.
- H. C. Jackson, A. M. Needham, L. J. Hutchins, S. E. Mazurkiewicz, and D. J. Heal, “Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat,” British Journal of Pharmacology, vol. 121, no. 8, pp. 1758–1762, 1997.
- S. K. Billes and M. A. Cowley, “Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis,” Neuropsychopharmacology, vol. 33, no. 6, pp. 1287–1297, 2008.
- G. H. Thomas, A. J. Babbs, R. E. Chatfield et al., “5-HT1A activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats,” Obesity, vol. 17, no. 3, pp. 467–473, 2009.
- Z. Abolfathi, J. Couture, F. Vallée, M. LeBel, M. Tanguay, and E. Masson, “A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 3, pp. 345–349, 2004.
- K. Noh, K. Bae, B. Min et al., “Enantioselective pharmacokinetics of sibutramine in rat,” Archives of Pharmacal Research, vol. 33, no. 2, pp. 267–273, 2010.
- B. E. Levin, “Sympathetic activity, age, sucrose preference, and diet-induced obesity,” Obesity Research, vol. 1, no. 4, pp. 281–287, 1993.
- B. E. Levin, “Reduced paraventricular nucleus norepinephrine responsiveness in obesity-prone rats,” American Journal of Physiology, vol. 270, no. 2, pp. R456–R461, 1996.
- B. E. Levin and A. A. Dunn-Meynell, “Maternal obesity alters adiposity and monoamine function in genetically predisposed offspring,” American Journal of Physiology, vol. 283, no. 5, pp. R1087–R1093, 2002.
- N. T. Bello, A. S. Guarda, C. E. Terrillion, G. W. Redgrave, J. W. Coughlin, and T. H. Moran, “Repeated binge access to a palatable food alters feeding behavior, hormone profile, and hindbrain c-Fos responses to a test meal in adult male rats,” American Journal of Physiology, vol. 297, no. 3, pp. R622–R631, 2009.
- G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinatesed, Academic Press, San Diego, Calif, USA, 4th edition, 1998.
- J. M. Overton, T. D. Williams, J. B. Chambers, and M. E. Rashotte, “Cardiovascular and metabolic responses to fasting and thermoneutrality are conserved in obese Zucker rats,” American Journal of Physiology, vol. 280, no. 4, pp. R1007–R1015, 2001.
- J. Woolard, T. Bennett, W. R. Dunn, D. J. Heal, S. Aspley, and S. M. Gardiner, “Acute cardiovascular effects of sibutramine in conscious rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 3, pp. 1102–1110, 2004.
- A. L. Birkenfeld, C. Schroeder, M. Boschmann et al., “Paradoxical effect of sibutramine on autonomic cardiovascular regulation,” Circulation, vol. 106, no. 19, pp. 2459–2465, 2002.
- C. Schroeder, J. Tank, M. Boschmann et al., “Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance,” Circulation, vol. 105, no. 3, pp. 347–353, 2002.
- S. Miyata, T. Hamamura, Y. Lee et al., “Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect,” Psychopharmacology, vol. 177, no. 3, pp. 289–295, 2005.
- M. W. Schwartz, S. C. Woods, D. Porte Jr., R. J. Seeley, and D. G. Baskin, “Central nervous system control of food intake,” Nature, vol. 404, no. 6778, pp. 661–671, 2000.
- Y. M. Kang, W. Ouyang, J. Y. Chen, J. T. Qiao, and N. Dafny, “Norepinephrine modulates single hypothalamic arcuate neurons via α1and β adrenergic receptors,” Brain Research, vol. 869, no. 1-2, pp. 146–157, 2000.
- G. S. Fraley and S. Ritter, “Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus,” Endocrinology, vol. 144, no. 1, pp. 75–83, 2003.
- B. E. Levin, “Reduced norepinephrine turnover in organs and brains of obesity-prone rats,” American Journal of Physiology, vol. 268, no. 2, pp. R389–R394, 1995.
- B. E. Levin, J. Triscari, and A. C. Sullivan, “The effect of diet and chronic obesity on brain catecholamine turnover in the rat,” Pharmacology Biochemistry and Behavior, vol. 24, no. 2, pp. 299–304, 1986.
- FDA, “Guidance for the clinical evaluation of weight-control drugs,” Critical Reviews in Food Science and Nutrition, vol. 41, pp. 91–94, 2001.